Psilocybin Trials Timeline

Psilocybin

Timeline

2020
1999

Dr. Roland Griffiths initiates a research program at Johns Hopkins University investigating the effects of psilocybin.

Resource: Johns Hopkins Magazine

2006

Dr. Roland Griffiths’ paper, “Psilocybin Can Occasion Mystical-Type Experiences Having Substantial and Sustained Personal Meaning and Spiritual Significance” is published in Psychopharmacology.

Source: Research Gate

Aug 14, 2008

The results of research from a team led by Dr. Charles Nichols at the Louisiana State University Health Sciences Center are published in The Journal of Pharmacology and Experimental Therapeutics.

Resource: LSU Health New Orleans, School of Medicine

2009

Dr. Robin Carhart-Harris founds the Psychedelic Research Group at Imperial College.

Resource: Imperial College London

Jan 2011

The results of a study examining the safety and efficacy of psilocybin as a treatment for advanced-cancer anxiety are published in the Archives of General Psychiatry.

Resource: Research Gate

Oct 29, 2014

Dr. Robin Carhart-Harris and his team at Imperial College produce a map of the brain’s internal communications and study the brain under the influence of psilocybin.

Resource: Imperial College London

Dec 2016

The results of research on the efficacy of psilocybin as a treatment for advanced-cancer anxiety and depression are published in the Journal of Psychopharmacology.

Resource: Research Gate

Aug 2017

Research conducted by MAPS on MDMA-Assisted Psychotherapy for PTSD is granted Breakthrough Therapy designation by the FDA. The FDA approves the MAPS protocol for Phase 3 clinical trials.

Resource: Multidisciplinary Association for Psychedelic Studies

Oct 23, 2018

The FDA grants Breakthrough Therapy designation to the European company, Compass Pathways, for its psilocybin therapy for treatment-resistant depression.

Resource: Compass Pathways

May 9, 2019

Denver, CO becomes the first city in the U.S. to decriminalize the cultivation, possession, and use of psilocybin mushrooms

Resource: Denverite

Sept 4, 2019

Johns Hopkins launches the Center for Psychedelic and Consciousness Research, focusing on how psychedelics affect behavior, mood, cognition, brain function, learning, memory, and biological markers of health.

Resource: The JHU Hub – John Hopkins University

Nov 22, 2019

The FDA grants Breakthrough Therapy designation to the Usona Institute for its psilocybin therapy for major depressive disorder.

Resource: Usona Institute

Psilocybin

Clinical Trial Data

Cancer Patients

80% of trial participants at 6-month stage following treatment were showing significantly reduced symptoms of anxiety and depression.

80% endorsing moderately or greater increased well-being/life satisfaction.

Estimated that only 33% of depression patients benefit from currently available treatment options.

Smoking Cessation

80% of participants were abstinent in the 6 month follow up, and 73% were biologically confirmed to have quit smoking (Chantix – best in class currently delivers a 35% quit rate).

12 month follow up showed 67% remained abstinent. In 2017, an additional follow up confirmed that 60% remained abstinent.

Post Traumatic Stress Disorder

300 million global sufferers.

76% of MDMA assisted psychotherapy patients were deemed to be successfully treated 12 months after therapy with similar results being seen with Psilocybin.